Imperfect Predictors for Lung Cancer Immunotherapy—A Field for Further Research

The armamentarium for lung cancer immunotherapy has been strengthened using two groups of monoclonal antibodies: 1) anti-PD-1 antibodies, including pembrolizumab and nivolumab, which block the programmed death 1 receptor on the lymphocyte surface, resulting in increasing activity of these cells, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wojas-Krawczyk, Kamila, Kubiatowski, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734866/
https://www.ncbi.nlm.nih.gov/pubmed/33330041
http://dx.doi.org/10.3389/fonc.2020.568174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734866/
https://www.ncbi.nlm.nih.gov/pubmed/33330041
http://dx.doi.org/10.3389/fonc.2020.568174

Ejemplares similares